cFluor® B548 Anti-Human CD14 (63D3)
The 63D3 monoclonal antibody binds to human CD14, a 53-55-kDa glycosylphosphatidylinositol (GPI)-linked membrane glycoprotein that works as a receptor on myeloid cells for ligands such as lipopolysaccharide (LPS)1. It is found that CD14 is a receptor for and binds to complexes of LPS and LBP with high affinity2. It expresses on monocytes and macrophages at high levels. It is also present in some interfollicular dendritic cells and macrophages, reticular dendritic cells, and Langerhans cells. The antibody was conjugated to a fluorophore and puriﬁed by afﬁnity chromatography.
Format: cFluor™ B548
Isotype: Mouse IgG1, κ
Tested Dilution: 5 μL / test
Application: Flow Cytometry
Storage: 2-8°C and protected from Light. Do not freeze
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% BSA (Origin USA)
Each lot of this antibody is quality control tested using flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per 1 million cells in a staining volume of 100 µL. If whole blood is analyzed, then use 5 µL per 100 µL. It is recommended that users titrate the antibody to obtain the optimal result for their specific application.
- Pugin J, et al. 1998. Infect Immun. 66:1174
- Wright SD, et al. 1990. Science. 249:1431
For Research Use Only. Not intended for use in diagnostic procedures.
*cFluor™ B548 is equivalent to CF®514 manufactured and provided by Biotium, Inc. under an Agreement between Biotium and Cytek (LICENSEE). The manufacture, use, sale, offer for sale, or import of the product is covered by one or more of the patents or pending applications owned or licensed by Biotium. The purchase of this product includes a limited, non-transferable immunity from suit under the foregoing patent claims for using only this amount of product for the purchaser’s own internal research. No right under any other patent claim, no right to perform any patented method, and no right to perform commercial services of any kind, including without limitation reporting the results of purchaser's activities for a fee or other commercial consideration, is conveyed expressly, by implication, or by estoppel.